drugset / Trial / NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
RandomizedSingle-groupOpen-labelTreatment
Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Timeline
- Start
- 2021-09-13
- Primary completion
- 2026-11
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-16673 | Other / unclassified | — | Oral |